Curious to see the emissions of the organizations you buy from or invest in?
Book a demo for a pilot project
Book a demo for a pilot project
GlaxoSmithKline Capital plc, commonly referred to as GSK, is a prominent player in the global healthcare industry, headquartered in Great Britain. Founded in 2000, GSK has established itself as a leader in pharmaceuticals, vaccines, and consumer healthcare, with significant operations across Europe, North America, and emerging markets.
The company is renowned for its innovative products, including treatments for respiratory diseases, HIV, and vaccines that protect against various infectious diseases. GSK's commitment to research and development has led to numerous breakthroughs, solidifying its market position as a trusted provider of healthcare solutions. With a focus on improving patient outcomes, GSK continues to achieve notable milestones, reinforcing its reputation as a key contributor to global health advancements.
+63 vs industry average
GlaxoSmithKline Capital plc’s score of 100 is higher than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Financial Intermediation has below-average carbon intensity
The Financial Intermediation industry has reduced its overall emissions by 33% since 2018
No reported emissions data is available for GlaxoSmithKline Capital plc yet.
As of the latest available data, GlaxoSmithKline Capital plc does not report specific carbon emissions figures. The company is a current subsidiary of GSK plc, which cascades its climate commitments and emissions data down to its subsidiaries.
GSK plc has set ambitious climate targets, including commitments to reduce greenhouse gas emissions across its operations. These initiatives are part of a broader strategy to achieve net-zero emissions by 2030 for its own operations (Scope 1 and 2) and by 2045 for its value chain (Scope 3).
The emissions data and reduction targets are inherited from GSK plc, which actively participates in various climate initiatives, including the Science Based Targets initiative (SBTi), the Carbon Disclosure Project (CDP), and the RE100 initiative. These commitments reflect GSK plc's dedication to sustainability and reducing its carbon footprint, which also impacts GlaxoSmithKline Capital plc as part of its corporate family.
While specific emissions data for GlaxoSmithKline Capital plc is not available, the overarching climate strategies and targets from GSK plc guide its environmental performance and commitments.
No climate goals have been disclosed for GlaxoSmithKline Capital plc yet.
No scope 3 category breakdown has been disclosed yet.


No peer comparison is available for GlaxoSmithKline Capital plc yet.
PCAF scored Scope 1, 2 and 3 for 2M+ organizations, including private ones.
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more